Pfizer halts final Trillium study, redirects R&D funds to cancer and obesity programs
read at Endpoints ↗Neutral
Pfizer announced it is ending the last clinical trial that originated from its 2021 purchase of Trillium Therapeutics.
The company said the decision will free up cash that will be redirected to a range of other research projects focused on cancer and obesity.
Pfizer also reported that its overall R&D spending is rising as it expands work on those therapeutic areas.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Pfizer ends Trillium-related development as R&D spend jumps”
read at Endpoints ↗84 words · retrieved May 5
comments(0)
5-min edit window · permanent after that